Public market insider buying at Greenbrook TMS (GTMS)

Public market insider buying at Greenbrook TMS (T:GTMS)

Lp 1315 Capital II, a 10% Holder, acquired 826,400 Common Shares on a direct ownership basis at a price of $2.000 on March 26th, 2020. This represents a $1,652,552 investment into the company's shares and an account share holdings change of 15.1%.

Greenbrook TMS is in the Healthcare Facilities & Services Sub Industry Group under the Healthcare Sector.

Greenbrook TMS Inc is a Canada-based company engaged in Clinics and Primary Care Services business sector. The Company operates from several treatment centers and it is a provider of Transcranial Magnetic Stimulation (TMS), non-invasive therapy for the treatment of Major Depressive Disorder (MDD) and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. These areas are known to be underactive in those diagnosed with depression, and stimulating these areas can improve the brain's ability to regulate mood. TMS Therapy can be used as stand-alone treatment or used in conjunction with medication.